longterm
efficaci
vaccin
determin
larg
part
gener
b
cell
memori
memori
b
cell
bmem
defend
previous
experienc
pathogen
differenti
antibodi
ab
secret
plasma
cell
pc
howev
certain
pathogen
drive
function
chang
bmem
compart
may
agedepend
contribut
chronic
recurr
infect
understand
characterist
divers
protect
ineffect
pathogen
bmem
respons
like
aid
develop
efficaci
vaccin
therapeut
ab
review
present
overview
bmem
cellular
subset
human
highlight
recent
method
allow
us
explor
bmem
ab
gene
repertoir
examin
known
human
bmem
ab
repertoir
observ
follow
vaccin
infect
agactiv
b
cell
receiv
cell
help
may
differenti
extrafollicular
shortliv
pc
gcdepend
bmem
gcindepend
bmem
figur
imag
studi
mice
indic
durabl
interact
b
cell
cognat
follicular
helper
cell
tfh
cell
b
cell
cell
border
spleen
lymph
node
provid
cell
help
promot
entri
b
cell
gc
gc
b
cell
undergo
affin
matur
shm
upon
cognat
interact
gc
th
cell
differenti
bmem
longliv
pc
mechan
regul
differenti
gc
b
cell
bmem
yet
well
understood
bmem
result
gc
reaction
mous
studi
indic
signal
via
cell
drive
differenti
gcindepend
bmem
cell
express
ab
fewer
mutat
low
affin
howev
clear
evid
human
studi
support
gcindepend
path
gener
human
bmem
tindepend
ag
polysaccharid
molecul
display
repeat
epitop
long
consid
incap
gener
memori
respons
howev
base
murin
studi
cell
found
predominantli
periton
caviti
margin
zone
b
cell
primari
precursor
tindepend
memori
human
b
cell
observ
human
peripher
blood
spleen
known
b
cell
subset
associ
ab
respons
tindepend
ag
sever
studi
includ
one
involv
immun
polysaccharid
vaccin
demonstr
igm
bmem
peripheri
deriv
splenic
margin
zone
b
cell
prediversifi
ig
repertoir
human
bmem
compart
believ
exclus
mostli
compos
classswitch
b
cell
howev
studi
demonstr
presenc
somat
mutat
igm
b
cell
b
cell
express
either
igm
alon
igm
igd
repres
igm
bmem
subset
gcdepend
igm
bmem
accept
origin
igmigd
subset
contenti
review
human
bmem
seifert
discuss
evid
gc
origin
igd
subset
includ
abil
reenter
gc
upon
secondari
challeng
b
tendenc
differenti
pc
c
longev
transcriptom
profil
thu
gcdepend
origin
igmigd
cell
support
character
bmem
peripher
blood
bmem
correspond
circul
splenic
margin
zone
b
cell
contribut
protect
bloodborn
tindepend
pathogen
pneumococc
polysaccharidespecif
bmem
display
somat
mutat
isol
post
immun
tindepend
vaccin
pneumovax
vesicular
stomat
virusebola
vaccin
gener
neutral
igm
respons
persist
despit
administr
booster
vaccin
studi
point
previous
underappreci
contribut
hypermut
igm
bmem
protect
pathogen
iggexpress
bmem
constitut
peripher
blood
b
lineag
cell
adult
structur
composit
ag
well
regulatori
factor
determin
igg
bmem
cell
class
switch
express
mainli
lesser
extent
exampl
includ
import
polysaccharidespecif
respons
protect
streptococcu
pneumonia
predomin
subclass
gener
hiv
ebola
viru
plasmodium
falciparum
respons
schistosoma
mansoni
howev
subclass
express
equal
efficaci
exampl
found
effect
neutral
hiv
major
igg
express
bmem
lack
express
bmem
cell
fewer
mutat
v
region
predominantli
express
subclass
subpopul
increas
elderli
hypothes
repres
exhaust
bmem
pool
igg
bmem
upon
reactiv
typic
differenti
pc
rather
reenter
gc
therefor
igg
subclass
also
import
aspect
ab
repertoir
consid
analys
data
set
igaexpress
bmem
associ
mucos
immun
respons
tend
aris
local
intestin
mucosaassoci
lymphoid
tissu
make
b
cell
peripheri
iga
bmem
evid
less
mutat
iga
cell
undergo
low
level
prolifer
express
polyreact
ab
phenotyp
indic
cell
gener
independ
gc
altern
earli
exit
gc
allow
broader
less
mutat
iga
bmem
could
crossprotect
relat
pathogen
enterotoxigen
e
coli
vibrio
cholera
recent
studi
demonstr
igm
bmem
share
gutspecif
gene
signatur
iga
bmem
relat
iga
clonotyp
could
switch
iga
upon
tdepend
independ
signal
sustain
ag
presenc
could
drive
protect
iga
respons
could
util
improv
oral
vaccin
although
presenc
ige
antibodi
causal
relationship
atop
diseas
allergi
asthma
well
establish
gener
well
understood
detect
low
level
human
peripher
blood
studi
mous
model
demonstr
potenti
sequenti
switch
wherein
cell
switch
ige
absecret
cell
anoth
studi
examin
repertoir
human
parent
bmem
progeni
studi
demonstr
high
affin
igesecret
pc
clone
deriv
select
expans
rare
high
affin
bmem
clone
without
undergo
mutat
antibodi
repertoir
analysi
ige
b
cell
patient
season
rhiniti
demonstr
v
gene
usag
limit
similar
across
multipl
patient
furthermor
peopl
parasit
infect
patient
atop
dermat
less
clonal
divers
lower
frequenc
shm
ige
repertoir
asthma
differ
reiter
import
examin
pathogendirect
ige
repertoir
context
specif
patholog
event
hiv
mycobacterium
tuberculosi
plasmodium
falciparum
hepat
c
viru
caus
chronic
infect
account
five
million
death
year
chronic
presenc
ag
prematur
abort
gc
extrafollicular
differenti
loss
surviv
nich
may
drive
expans
phenotyp
function
alter
bmem
subset
refer
exhaust
tissuelik
atyp
bmem
figur
distinct
typic
bmem
atyp
bmem
express
stimul
via
bcr
subsequ
produc
ab
hivassoci
cell
express
high
level
express
tbet
inhibitori
receptor
fc
receptor
like
fcrl
famili
distinguish
b
cell
subset
resembl
cell
resid
tonsil
defin
tissuelik
bmem
tonsillar
b
cell
undergon
isotyp
switch
shm
similar
bmem
nonrespons
stimul
bcr
crosslink
atyp
bmem
also
observ
increas
frequenc
individu
chronic
hcv
infect
activ
latent
tb
infect
similarli
expand
subset
atyp
bmem
observ
repeatedli
infect
p
falciparum
atyp
bmem
patient
malaria
express
rather
express
observ
tissuelik
bmem
hiv
keep
exhaust
phenotyp
atyp
cell
refract
bcr
crosslink
cpg
stimul
compar
bmem
tbetexpress
b
cell
observ
individu
autoimmun
condit
rheumatoid
arthriti
system
lupu
erythematosu
like
differ
phenotyp
function
cell
aris
chronic
infect
chronic
immun
stimul
inflamm
figur
thought
contribut
expans
atyp
bmem
unabl
secret
ab
could
explain
lack
acquisit
immun
chronic
infect
method
use
produc
human
monoclon
ab
mab
includ
combinatori
display
librari
b
cell
immort
singlecel
express
clone
hybridoma
gener
figur
method
use
improv
understand
bmem
repertoir
gener
combinatori
display
librari
singlechain
variabl
fragment
scfv
agbind
fragment
fab
figur
highthroughput
screen
method
allow
discoveri
sever
pathogenneutr
ab
librari
ab
v
gene
gener
b
cell
isol
individu
postimmun
postinfect
random
pair
h
l
chain
gene
express
phage
yeast
mammalian
cell
agspecif
abexpress
cell
particl
select
clone
mammalian
cell
mab
express
sinc
h
l
chain
pair
occur
randomli
process
result
ab
repres
pair
may
occur
natur
immun
system
techniqu
allow
gener
higher
affin
ab
allow
character
properlypair
agspecif
b
cell
repertoir
b
cell
immort
figur
involv
transform
bmem
use
epstein
barr
viru
ebv
presenc
tlr
tolllik
receptor
agonist
cpg
dna
total
blood
lymphocyt
isol
igg
bmem
typic
cultur
ebv
cpg
andor
addit
costimul
week
allow
prolifer
b
cell
secret
ab
supernat
cultur
harvest
test
agspecif
ab
individu
ig
h
l
chain
pair
clone
sequenc
ebvtransform
b
cell
allow
bmem
analysi
requir
screen
signific
number
cell
identifi
bmem
interest
bmem
also
immort
forc
express
bclxl
cultur
presenc
plasmablastlik
transduc
cell
secret
ab
supernat
plasmablast
amen
immort
recent
studi
demonstr
bmem
plasmablast
cultur
vitro
figur
without
immort
ab
product
singlecel
express
clone
involv
applic
revers
transcriptionpolymeras
chain
reaction
rtpcr
singlecel
level
amplif
ig
h
l
chain
gene
clone
express
mammalian
cell
line
figur
plasmablast
bmem
sort
individu
postvaccin
postinfect
gener
human
mab
singlecel
express
clone
techniqu
involv
specif
pcr
amplif
ab
transcript
individu
cell
technic
challeng
depend
upon
high
qualiti
primer
applic
singlecel
express
clone
repertoir
analys
difficult
peripher
b
cell
subset
fewer
ig
transcript
per
cell
plasmablast
plasmablast
secret
larger
quantiti
ig
amen
type
protocol
although
number
circul
plasmablast
typic
low
healthi
individu
day
vaccin
infect
transient
larg
popul
agspecif
igsecret
cell
easili
isol
popul
distinguish
igg
bmem
popul
peak
week
postimmun
plasmablast
sort
human
pbmc
week
vaccin
influenza
bacillu
anthraci
streptococcu
pneumonia
success
yield
agspecif
high
affin
mab
agspecif
plasmablast
bmem
isol
fluorescenceactiv
cell
sort
fac
use
reagent
bind
agspecif
cell
ag
bait
igg
pc
plasmablast
difficult
isol
agspecif
manner
due
limit
surfac
express
ig
howev
flow
cytometrybas
ig
captur
assay
establish
sort
igg
agspecif
plasmablast
three
vaccin
ag
name
hiv
tetanu
toxin
hepat
b
surfac
ag
method
captur
secret
ab
plasmablast
enabl
fluoresc
ag
probe
identifi
agspecif
cell
isol
agspecif
human
bmem
also
challeng
sinc
circul
low
frequenc
peripheri
expand
vitro
immort
use
ebvtransform
techniqu
mention
earlier
recent
studi
isol
human
bmem
demonstr
vitro
booster
vaccin
consist
streptavidinco
nanoparticl
conjug
biotinyl
ag
cpg
dna
gener
agspecif
mab
period
day
tradit
mab
gener
method
hybridoma
technolog
figur
involv
product
ab
hybridoma
clone
form
fusion
myeloma
cell
b
cell
donor
immun
anim
although
method
gener
high
affin
mab
combin
transgen
human
mous
strain
obtain
fulli
human
mab
abil
accur
perform
deep
sequenc
ab
vdj
region
provid
valuabl
insight
regul
evolut
bmem
repertoir
rapidli
develop
highthroughput
nextgener
sequenc
technolog
achiev
high
resolut
number
singl
chain
sequenc
one
experi
howev
inform
endogen
pair
ighigl
gene
obtain
singl
chain
sequenc
hinder
accur
represent
b
cell
repertoir
suggest
improv
method
templat
prepar
sequenc
imag
data
analysi
requir
accur
effici
larg
scale
analysi
function
ab
repertoir
recent
develop
ultra
highthroughput
method
amplifi
ighigl
gene
b
cell
captur
within
droplet
creat
singl
dna
amplicon
allow
sequenc
pair
chain
addit
simultan
sequenc
barcod
ig
gene
along
coexpress
function
gene
better
repres
ab
repertoir
combin
larg
dataset
sever
read
deep
sequenc
b
cell
ab
repertoir
sequenc
bcrrepseq
data
mass
spectrometri
serum
ab
igseq
allow
comparison
ab
repertoir
two
compart
singlecel
rnaseq
technolog
typic
gener
larg
dataset
requir
bioinformat
tool
expertis
deconvolut
interpret
sever
pipelin
develop
bcr
sequenc
analysi
like
continu
evolv
accommod
data
complex
cost
per
kilobas
highthroughput
sequenc
ht
drop
past
year
alon
seen
rapid
increas
number
publish
resourc
analysi
bcell
sequenc
data
tabl
discuss
techniqu
outlin
appli
bmem
subset
allow
improv
understand
develop
differenti
specif
diseas
postvaccin
signific
research
mab
therapeut
multidrug
resist
gram
neg
bacteria
review
knowledg
shape
human
bmem
repertoir
lack
deserv
attent
reader
also
refer
three
studi
bmem
repertoir
vibrio
cholera
klebsiella
pneumonia
hemophilu
influenza
articl
focus
gram
posit
infect
larger
number
publish
studi
avail
analysi
bacillu
anthraci
gram
posit
rodshap
bacteria
caus
seriou
often
fatal
infect
human
alarmingli
b
anthraci
use
biolog
weapon
highlight
serious
anthrax
diseas
antibiot
use
anthrax
treatment
postexposur
prophylaxi
use
fda
approv
anthrax
vaccin
adsorb
ava
restrict
militari
personnel
might
face
occup
anthrax
exposur
ava
predominantli
compos
protect
ag
pa
compon
tripartit
anthrax
exotoxin
ava
elicit
toxin
neutral
ab
protect
gener
protect
respons
requir
multipl
vaccin
ongo
annual
booster
vaccin
gener
protect
shortliv
antipa
igg
respons
human
human
anim
studi
use
ava
demonstr
longliv
antipa
bmem
respons
use
mab
paspecif
b
cell
isol
seven
avavaccin
individu
reason
cowork
show
although
major
mab
bound
specif
kda
region
pa
monom
vh
region
sequenc
analysi
reveal
uniqu
gene
rearrang
absecret
cell
also
isol
individu
day
follow
ava
recombin
pa
vaccin
gener
character
human
paspecif
mab
sever
mab
demonstr
vitro
toxin
neutral
protect
vivo
follow
challeng
mice
bioactiv
anthrax
toxin
sever
paspecif
mab
develop
recombin
human
mab
raxibacumab
one
approv
use
treatment
inhal
anthrax
clostridium
tetani
secret
tetanu
toxin
respons
symptom
associ
tetanu
diseas
sinc
introduct
tetanu
toxoid
tt
contain
vaccin
incid
report
tetanu
case
unit
state
declin
per
popul
per
popul
tetanusspecif
ab
repertoir
character
sever
group
use
differ
method
analysi
fab
librari
creat
plasmablast
isol
day
posttt
vaccin
indic
b
cell
clone
hypermut
variant
compris
human
polyclon
ab
repertoir
followup
studi
examin
plasmablast
v
gene
region
tt
vaccin
suggest
major
b
cell
clone
develop
respons
singl
vaccin
event
librari
creat
use
singl
human
vl
region
pair
collect
vh
region
result
divers
high
affin
ab
ttspecif
encod
sole
vh
lavind
cowork
use
highresolut
liquid
chromatographi
tandem
ms
proteom
analys
serum
ab
coupl
nextgener
sequenc
v
gene
repertoir
peripher
b
cell
understand
serum
igg
b
cell
repertoir
follow
tt
booster
vaccin
studi
confirm
previou
find
tt
serum
igg
compris
clonotyp
found
clonotyp
account
respons
plasmablast
clonotyp
account
ab
detect
serum
month
postvaccin
tt
vaccin
effect
prevent
tetanu
character
bmem
repertoir
gener
respons
vaccin
provid
inform
valuabl
improv
vaccin
pathogen
streptococcu
pneumonia
caus
agent
communityacquir
pneumonia
health
care
burden
worsen
antibiot
resist
despit
effect
vaccin
lack
adequ
coverag
especi
adult
result
larg
atrisk
popul
problem
compound
serotyp
repres
current
vaccin
ab
repertoir
respons
vaccin
polysaccharid
vaccin
conjug
vaccin
examin
fulllength
fulli
human
serotypespecif
mab
anticel
wall
polysaccharid
mab
gener
individu
day
postvaccin
examin
v
gene
usag
clonal
famili
zhou
colleagu
gener
human
fab
fragment
specif
capsular
polysaccharid
pneumonia
strain
determin
h
l
chain
variabl
gene
usag
bmemderiv
human
hybridoma
gener
recipi
conjug
vaccin
studi
structurefunct
correl
mab
may
affect
b
cell
repertoir
invas
pneumococc
infect
differ
method
util
examin
ab
repertoir
studi
cite
demonstr
increas
frequenc
shm
respons
primari
vaccin
suggest
recipi
either
asymptomat
carrier
previous
expos
wildtyp
strain
pneumonia
allow
vaccin
elicit
memori
respons
furthermor
studi
also
reveal
ab
repertoir
across
individu
oligoclon
base
limit
usag
vh
vl
famili
similar
h
l
pair
specif
serotyp
two
studi
identifi
iga
h
chain
match
ab
isotyp
respons
found
donor
sera
indic
fab
ab
deriv
respons
pneumonia
infect
character
fulllength
fulli
human
serotypespecif
mab
reveal
preferenti
use
lambda
kappa
light
chain
respons
certain
serotyp
emerg
pneumonia
serotyp
cover
vaccin
driven
effort
develop
univers
vaccin
serotypespecif
pneumococc
surfac
protein
pspa
found
pneumonia
isol
studi
examin
ab
respons
prolinerich
region
indic
pspa
may
good
vaccin
candid
detail
examin
human
antipspa
ab
repertoir
would
allow
better
understand
efficaci
pspabas
vaccin
plasmodium
falciparum
mosquitoborn
parasit
caus
malaria
accord
cdc
malaria
caus
estim
million
case
malaria
death
worldwid
repeat
exposur
older
children
adult
slowli
develop
resist
sever
ill
death
never
achiev
complet
resist
infect
human
p
falciparum
infect
gener
longliv
atyp
bmem
respons
develop
slowli
mani
year
malaria
exposur
limit
magnitud
neutral
igg
ab
produc
atyp
bmem
seen
malaria
infect
adult
differ
v
region
repertoir
ab
produc
classic
bmem
similar
studi
examin
v
gene
ab
children
found
differ
classic
atyp
bmem
repertoir
infant
immun
repertoir
poorli
character
thought
limit
abil
respond
ag
challeng
recent
studi
isol
bmem
infant
toddler
preinfect
acut
malaria
infect
examin
ab
repertoir
use
method
known
molecular
identifi
clusteringbas
immun
repertoir
sequenc
studi
found
infant
bmem
could
acquir
mutat
per
h
chain
v
region
respons
malaria
infect
breadth
repertoir
achiev
compar
young
adult
expos
malaria
also
observ
upon
malaria
rechalleng
bmem
toddler
previous
expos
malaria
could
undergo
mutat
retain
igm
express
abil
sequenc
analyz
immun
repertoir
even
small
sampl
allow
better
understand
infant
bmem
compart
turn
inform
vaccin
design
strategi
prevent
malaria
age
group
influenza
viru
caus
annual
epidem
pose
signific
risk
mortal
immunocompromis
individu
elderli
year
young
children
year
due
abil
constantli
evolv
adapt
univers
influenza
vaccin
elud
investig
neutral
ab
respons
viral
infect
vaccin
mainli
target
glycoprotein
hemagglutinin
ha
prevent
entri
target
cell
ab
direct
second
glycoprotein
neuraminidas
na
prevent
viru
exit
spread
ab
target
ha
globular
head
limit
breadth
effort
gener
broadli
neutral
ab
focu
target
ha
stem
region
conserv
across
strain
ab
neutral
strain
clade
discov
sever
group
use
phage
display
immort
bmem
cell
high
affin
human
ab
clone
igg
absecret
cell
week
vaccin
studi
observ
repertoir
limit
clonal
accumul
somat
mutat
within
clone
result
extens
intraclon
divers
recent
studi
examin
haspecif
bmem
repertoir
three
unrel
individu
known
bcr
crossreact
ha
group
influenza
virus
character
clonal
lineag
determin
germlin
receptor
capac
recogn
epitop
head
ha
trimer
diverg
influenza
subtyp
subtyp
furthermor
show
clonal
relat
ab
bound
ha
via
long
loop
length
relat
amino
acid
sequenc
crossreact
ab
bound
differ
affin
suggest
sequenti
exposur
influenza
subtyp
may
driven
affin
matur
ab
ab
repertoir
analys
reveal
presenc
signatur
sequenc
key
somat
mutat
preferenti
vh
gene
usag
gener
broadli
neutral
antiinfluenza
ab
human
immunodefici
viru
infect
estim
million
peopl
unit
state
end
errorpron
revers
transcriptas
abil
replic
rapidli
multipl
variant
hiv
coexist
host
allow
success
evas
innat
adapt
immun
respons
expos
hiv
envelop
glycoprotein
env
access
ab
hiv
evolv
mechan
avoid
recognit
ab
evas
mechan
employ
hiv
includ
gener
amino
acid
chang
variabl
region
env
close
space
nglycan
prevent
ab
recognit
env
chronic
individu
develop
antienv
broadli
neutral
ab
ab
increas
shm
activationinduc
cytidin
aminas
mediat
insert
delet
h
l
chain
sequenc
long
selfreact
envspecif
singl
bmem
sort
macaqu
day
immun
vdj
sequenc
examin
reveal
uniqu
clonotyp
function
sequenc
anoth
studi
examin
bmem
repertoir
gener
chronic
infect
individu
report
respons
oligoclon
clonotyp
observ
high
level
shm
observ
restrict
broadlyneutr
ab
atyp
exhaust
bmem
identifi
chronic
hivinfect
individu
demonstr
fewer
shm
lower
hiv
neutral
capac
rest
bmemderiv
mab
bmem
immort
vitro
bmem
differenti
nextgener
sequenc
techniqu
also
appli
sampl
obtain
infect
donor
gener
examin
ab
repertoir
hivneutr
capac
detail
inform
regard
differ
ab
repertoir
vaccin
model
chronic
infect
individu
review
elsewher
dengu
viru
denv
mosquitoborn
viru
infect
estim
million
peopl
yearli
tradit
understand
bmem
function
cell
provid
mean
rapidli
respond
pathogen
upon
repeat
exposur
provid
protect
diseas
denv
infect
howev
sequenti
infect
one
serotyp
common
ab
memori
respons
primari
infect
worsen
secondari
infect
caus
heterolog
dengu
viru
halstead
propos
abdepend
enhanc
ade
explain
sever
secondari
infect
crossreact
nonneutr
ab
gener
primari
respons
form
agab
complex
upon
secondari
infect
heterolog
denv
serotyp
crossreact
ab
bind
fc
receptor
allow
effici
viral
entri
replic
fcexpress
cell
result
exacerb
diseas
role
ade
underscor
discoveri
nonneutr
crossreact
ab
gener
sort
igg
bmem
denvinfect
individu
acut
denv
infect
result
larg
rapid
virusspecif
plasmablast
respons
mab
deriv
plasmablast
patient
secondari
denv
infect
reveal
repertoir
highli
affin
matur
clonal
expand
mab
also
demonstr
crossreact
denv
serotyp
bind
neutral
appanna
colleagu
sort
plasmablast
agspecif
bmem
patient
reinfect
denv
examin
ab
repertoir
conclud
plasmablast
respons
repres
fraction
bmem
repertoir
studi
emphas
need
examin
b
lineag
compart
complet
understand
humor
respons
recent
denvexpos
volunt
vaccin
live
attenu
tetraval
vaccin
butantandv
day
later
plasmablast
isol
gener
neutral
ab
immun
result
neutral
ab
previou
exposur
denv
type
well
six
mab
neutral
three
serotyp
addit
denv
surfac
glycoprotein
e
main
target
neutral
ab
contain
region
highli
conserv
denv
reemerg
zika
viru
zikv
result
immunolog
crossreact
mab
gener
plasmablast
denvinfect
individu
crossreact
zikv
zikvspecif
mab
bmem
primari
zikvinfect
individu
histori
denv
infect
crossreact
denv
e
protein
cdc
design
clostridioid
difficil
c
difficil
previous
clostridium
difficil
carbapenemresist
enterobacteriacea
antibioticresist
neisseria
gonorrhea
urgent
threat
due
challeng
antibiot
resist
pathogen
emphasi
gener
novel
therapeut
howev
best
knowledg
ab
repertoir
respons
infect
yet
examin
clostridioid
difficil
sporeform
gram
posit
bacteria
lead
caus
nosocomi
infect
industri
nation
least
new
case
estim
us
everi
year
c
difficil
infect
cdi
longer
restrict
health
care
facil
cdi
potenti
debilit
ill
rang
mild
diarrhea
lifethreaten
pseudomembran
enterocol
caus
two
c
difficil
exotoxin
toxin
tcda
toxin
b
tcdb
exist
recurr
cdi
suggest
misdirect
memori
respons
emerg
new
hypervirul
ribotyp
pose
signific
challeng
develop
appropri
vaccin
therapeut
sever
vaccin
mab
target
tcda
tcdb
introduc
clinic
trial
sever
develop
address
treatment
prevent
infect
bezlotoxumab
human
mab
bind
tcdb
approv
us
fda
treat
recurr
cdi
target
toxin
therapi
seem
appropri
consid
studi
demonstr
antitoxin
circul
ab
bmem
respons
certain
individu
c
difficileassoci
diarrhea
bmem
respons
ctermin
domain
ctd
fragment
tcdb
histori
cdi
result
murin
studi
indic
immun
ctd
histor
strain
gener
robust
recal
respons
neutral
ab
protect
lethal
challeng
ctd
hypervirul
strain
gener
slow
bmem
respons
toxinneutr
ab
delay
death
postleth
challeng
interestingli
although
tcdb
two
strain
share
homolog
antictd
ab
gener
immun
anim
model
cross
neutral
toxin
furthermor
low
serum
concentr
antitcda
ab
link
recurr
underscor
need
examin
depth
ab
respons
individu
histori
cdi
compar
respons
suffer
recurr
specif
understand
bmem
compart
provid
insight
diseas
recurr
support
better
treatment
strategi
recent
outbreak
ebola
zika
viru
acceler
research
develop
treatment
counter
threat
renew
research
effort
led
sever
therapeut
vaccin
candid
ebola
flavivirus
zika
west
nile
viru
provid
import
inform
immun
repertoir
individu
vaccin
infect
virus
chikungunya
viru
chikv
mosquitoborn
alpha
viru
first
isol
tanzania
emerg
worldwid
threat
licens
vaccin
therapi
avail
current
prevent
treat
chikv
immun
respons
chikv
infect
fulli
understood
multipl
studi
demonstr
role
passiv
immunotherapi
control
chikv
infect
although
great
stride
made
identifi
character
neutral
mab
therapeut
ab
typic
deriv
individu
expand
ab
repertoir
studi
includ
sampl
account
variabl
age
gender
immunecompet
comorbid
time
postinfect
would
invalu
design
appropri
prevent
treatment
strategi
emerg
infect
recent
advanc
cellular
molecular
comput
techniqu
provid
detail
insight
specif
breadth
ab
respons
indepth
knowledg
reveal
nuanc
immun
system
capac
gener
pathogenspecif
respons
describ
review
sever
consider
need
taken
account
undertak
arduou
task
examin
specif
b
cell
singl
cell
level
addit
success
transit
toward
clinic
applic
requir
understand
infect
pathogen
vaccin
cell
subset
examin
technolog
avail
ultim
care
interpret
data
pathogen
hiv
malaria
lead
atyp
memori
hiv
influenza
constantli
adapt
evad
immun
system
pneumonia
sever
strain
dengu
viru
worsen
clinic
diseas
upon
reinfect
primari
infect
c
difficil
render
host
prone
recurr
infect
therefor
understand
pathogen
mechan
action
allow
better
select
antigen
target
gener
broadli
neutral
ab
select
cell
subset
examin
crucial
specif
bmem
rare
avail
month
acut
respons
subsid
ab
repertoir
reflect
wider
respons
provid
histor
perspect
specif
respons
plasmablast
peak
shortli
vaccin
infect
requir
agspecif
bait
isol
repertoir
typic
repres
current
respons
pc
rare
peripheri
gener
vitro
bmem
differenti
provid
inform
exist
memori
methodolog
take
account
influenc
tissu
microenviron
fulli
recreat
ex
vivo
acquir
consider
inform
agspecif
b
cell
repertoir
begun
explor
possibl
exist
bcr
public
lineagesclonotyp
respons
infect
public
clonotyp
describ
presenc
domin
nearli
ident
vdj
amino
acid
sequenc
across
multipl
individu
better
studi
context
cell
rather
b
cell
analyz
ig
sequenc
share
across
multipl
individu
invalu
understand
clonotyp
emerg
overal
adapt
respons
specif
pathogen
addit
infecti
diseas
analysi
b
cell
repertoir
improv
abil
detect
immun
system
disord
elucid
possibl
mechan
caus
exampl
rheumatoid
arthriti
ra
system
autoimmun
diseas
often
involv
product
anticitrullin
protein
ab
ab
sequenc
ra
patient
defin
autoantibodi
specif
provid
insight
clinic
diseas
mechan
lead
break
toler
increas
proinflammatori
activ
common
variabl
immun
defici
analysi
ig
h
chain
gene
rearrang
demonstr
abnorm
vdj
rearrang
format
suggest
earli
differ
b
cell
select
develop
patient
final
ab
studi
pivot
demonstr
clonal
origin
multipl
myeloma
recent
sequenc
technolog
defin
patient
ab
repertoir
appli
clinic
diseas
detect
assess
therapeut
respons
myeloma
well
leukemia
consid
knowledg
tool
avail
us
goal
develop
precis
person
therapeut
come
closer
fruition
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
